GlassScriptPhysician profile
David W Hojnacki
NPI 1205848306
$479,571.95
in general payments reported to CMS, 2019-2025
20 companies · $54K in 2025
The $54K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182K · 2020: $89K · 2021: $28K · 2022: $24K · 2023: $43K · 2024: $59K · 2025: $54K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $123K · Consulting Fee: $17K · Travel and Lodging: $12K · Food and Beverage: $4,364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $122,742.00 |
| Consulting Fee | $16,866.00 |
| Travel and Lodging | $12,261.01 |
| Food and Beverage | $4,363.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $195,567.72 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Emd Serono, INC. | $104,091.78 | 2019-2025 | Mavenclad |
| Celgene Corporation | $82,095.96 | 2019-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $38,101.38 | 2019-2025 | |
| Genentech USA, INC. | $25,760.77 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Alexion Pharmaceuticals, INC. | $19,545.22 | 2019-2025 | Ultomiris |
| Amgen INC. | $9,512.26 | 2024-2025 | Uplizna |
| E.R. Squibb & Sons, L.L.C. | $4,080.62 | 2021 | |
| Tg Therapeutics, INC. | $341.14 | 2024-2025 | |
| Pfizer INC. | $122.21 | 2024-2025 | |
| Genzyme Corporation | $81.11 | 2021-2025 | |
| Csl Behring | $66.17 | 2022-2024 | Hizentra |
| Janssen Pharmaceuticals, INC | $45.17 | 2022 | |
| Neurelis, INC. | $37.89 | 2020-2023 | Valtoco |
| Ucb, INC. | $24.61 | 2025 | Rystiggo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $23.76 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $22.20 | 2025 | Wainua |
| Argenx US, INC. | $18.41 | 2025 | Vyvgart |
| Mallinckrodt Hospital Products INC. | $18.34 | 2022 | |
| Horizon Therapeutics Plc | $15.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hojnacki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.